No Data
No Data
RBC Capital Initiates Cidara Therapeutics(CDTX.US) With Buy Rating, Announces Target Price $34
RBC Initiates Cidara Therapeutics at Outperform, Speculative Risk, With $34 Price Target
WBB Securities Initiates Cidara Therapeutics(CDTX.US) With Buy Rating, Announces Target Price $45
Express News | WBB Securities Maintains Strong Buy on Cidara Therapeutics, Raises Price Target to $45
Cidara Therapeutics Analyst Ratings
Express News | Cidara Therapeutics Completes Enrollment of Phase 2B Navigate Trial Evaluating Cd388 for Prevention of Seasonal Influenza
Unlock the Full List